

I hereby certify that this correspondence is being filed via
EFS-Web with the United States Patent and Trademark Office
on Mar. 30, 2007

PATENT
Attorney Docket No.: 015280-368240US
Client Reference No.: E-268-1997/2-US-02

TOWNSEND and TOWNSEND and CREW LLP

By: 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Jay A. Berzofsky et al.

Application No.: 10/815,340

Filed: March 30, 2004

For: MUCOSAL CYTOTOXIC T
LYMPHOCYTE RESPONSES

Confirmation No.: 8261

Examiner: Nicole Kinsey

Art Unit: 1645

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER
37 CFR §1.97 and §1.98

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references, in compliance with the requirements of 37 CFR §1.98(a)(2), are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.


As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Date: March 30, 2007

By:


Nicholas V. Sherbina
Reg. No. 54,443

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 206-467-9600
Fax: 206-623-6793
NVS:jms
61015212 v1

Substitute for form 1449A&B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/815,340
				Filing Date	March 30, 2004
				First Named Inventor	Berzofsky, Jay A.
				Art Unit	1645
				Examiner Name	Nicole Kinsey
Sheet	1	of	2	Attorney Docket Number	015280-368240US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AA	Ahmed and Gray, "Immunological memory and protective immunity: understanding their relation," <i>Science</i> 272:54-60 (1996).	<input type="checkbox"/>
	AB	Bender <i>et al.</i> , "Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza," <i>J. Virol.</i> 70:6418-6424 (1996).	<input type="checkbox"/>
	AC	Bennink <i>et al.</i> , "Influenza pneumonia: early appearance of cross-reactive T cells in lungs of mice primed with heterologous type A viruses," <i>Immunol.</i> 35:503-509 (1978).	<input type="checkbox"/>
	AD	Chen <i>et al.</i> , "Predominant T-cell receptor V β usage of intraepithelial lymphocytes during the immune response to enteric reovirus infection," <i>J. Virol.</i> 71:3431-3436 (1997).	<input type="checkbox"/>
	AE	Ehl <i>et al.</i> , "A functional and kinetic comparison of antiviral effector and memory cytotoxic T lymphocyte populations <i>in vivo</i> and <i>in vitro</i> ," <i>Eur. J. Immunol.</i> 27:3404-3413 (1997).	<input type="checkbox"/>
	AF	Epstein <i>et al.</i> , "Mechanism of protective immunity against influenza virus infection in mice without antibodies," <i>J. Immunol.</i> 160:322-327 (1998).	<input type="checkbox"/>
	AG	Gallichan and Rosenthal, "Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization," <i>J. Exp. Med.</i> 184:1879-1890 (1996).	<input type="checkbox"/>
	AH	Gurgo <i>et al.</i> , "Envelope sequences of two new United States HIV-1 isolates," <i>Virology</i> 164:531-536 (1988).	<input type="checkbox"/>
	AI	Kulkarni <i>et al.</i> , "Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus," <i>J. Virol.</i> 69:1261-1264 (1995).	<input type="checkbox"/>
	AJ	Kundig <i>et al.</i> , "On the role of antigen in maintaining cytotoxic T-cell memory," <i>Proc. Natl. Acad. Sci. USA</i> 93:9716-9723 (1996).	<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/815,340
				Filing Date	March 30, 2004
				First Named Inventor	Berzofsky, Jay A.
				Art Unit	1645
				Examiner Name	Nicole Kinsey
Sheet	2	of	2	Attorney Docket Number	015280-368240US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	AK	Lohman <i>et al.</i> , "Antiviral cytotoxic T lymphocytes in vaginal mucosa of simian immunodeficiency virus-infected rhesus macaques," <i>J. Immunol.</i> 155:5855-5860 (1995).	<input type="checkbox"/>	
	AL	Miller <i>et al.</i> , "Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239," <i>J. Virol.</i> 71:1911-1921 (1997).	<input type="checkbox"/>	
	AM	Putkonen <i>et al.</i> , "Protection of human immunodeficiency virus type 2-exposed seronegative macaques from mucosal simian immunodeficiency virus transmission," <i>J. Virol.</i> 71:4981-4984 (1997).	<input type="checkbox"/>	
	AN	Quesada-Rolander <i>et al.</i> , "Protection against mucosal SIV _{sm} challenge in macaques infected with a chimeric SIV that expresses HIV type 1 envelope," <i>AIDS Res. Hum. Retroviruses</i> 12:993-999 (1996).	<input type="checkbox"/>	
	AO	Ratner <i>et al.</i> , "Complete nucleotide sequence of the AIDS virus, HTLV-III," <i>Nature</i> 313:277-284 (1985).	<input type="checkbox"/>	
	AP	Rosenthal and Gallichan, "Challenges for vaccination against sexually-transmitted diseases: induction and long-term maintenance of mucosal immune responses in the female genital tract," <i>Semin. Immunol.</i> 9:303-314 (1997).	<input type="checkbox"/>	
	AQ	Sydora <i>et al.</i> , "Intestinal intraepithelial lymphocytes respond to systemic lymphocytic choriomeningitis virus infection," <i>Cell. Immunol.</i> 167:161-169 (1996).	<input type="checkbox"/>	
	AR	Takahashi <i>et al.</i> , "A single amino acid interchange yields reciprocal CTL specificities for HIV-1 gp160," <i>Science</i> 246:118-121 (1989).	<input type="checkbox"/>	
	AS	Taylor and Askonas, "Influenza nucleoprotein-specific cytotoxic T-cell clones are protective <i>in vivo</i> ," <i>Immunol.</i> 58:417-420 (1986).	<input type="checkbox"/>	
	AT	Wang <i>et al.</i> , "Mucosal immunization with a DNA vaccine induces immune responses against HIV-1 at a mucosal site," <i>Vaccine</i> 15:821-825 (1997).	<input type="checkbox"/>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.